foslevodopa   Click here for help

GtoPdb Ligand ID: 13174

Synonyms: Dopa 4-phosphate
Approved drug
foslevodopa is an approved drug (EMA (2022))
Compound class: Synthetic organic
Comment: Foslevodopa is a water-soluble levodopa prodrug.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 5
Rotatable bonds 5
Topological polar surface area 160.12
Molecular weight 277.17
XLogP -4.49
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=C(C[C@@H](C(=O)O)N)C=C(C(=C1)OP(=O)(O)O)O
Isomeric SMILES C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)OP(=O)(O)O
InChI InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1
InChI Key YNDMEEULGSTYJT-LURJTMIESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
A combination product (Produodopa®:; ABBV-951) containing foslevodopa and the carbidopa prodrug foscarbidopa was approved by EU EMA and UK MHRA (in the third quarter of 2022), with clinical use beginning in early 2024. Produodopa is indicated as a 24-hour subcutaneous infusion therapy for the treatment of advanced Parkinson's disease motor fluctuations. This same comnination product was approved by the FDA in October 2024 (as Vyalev®).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04380142 Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease Phase 3 Interventional AbbVie 2
NCT03781167 A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD) Phase 3 Interventional AbbVie 1
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)